1%
hlights – P&L (In ₹ Mn) Q3 FY24 Q3 FY23 Y-o-Y Gr% Y-o-Y performance Revenue 11,556 11,461 1% Value Added Value Added % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9%
57.0%
ance Revenue 11,556 11,461 1% Value Added Value Added % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth
21.7%
11,556 11,461 1% Value Added Value Added % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth was higher as
10.9%
1 1% Value Added Value Added % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth was higher as compared to va
48.4%
dded Value Added % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth was higher as compared to value growth. S
20.2%
ded % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth was higher as compared to value growth. Sales in the US
10.8%
EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth was higher as compared to value growth. Sales in the US region grew w
19%
% PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth was higher as compared to value growth. Sales in the US region grew well,
8%
AT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 5,544 48.4% 2,313 20.2% 1,243 10.8% 19% 8% 1% Volumes growth was higher as compared to value growth. Sales in the US region grew well, led
3%
lights – P&L (In ₹ Mn) Q3 FY24 Q2 FY24 Q-o-Q Gr% Q-o-Q performance Revenue 11,556 11,895 (3%) Revenue is down primarily because of reduction in prices of Paracetamol across all regions. Val
51.7%
dded Value Added % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 6,144 51.7% 2,130 17.9% 1,021 8.6% 7% VA% is significantly better due to better product mix (increase in
17.9%
ded % EBITDA EBITDA % PAT PAT % 6,583 57.0% 2,505 21.7% 1,257 10.9% 6,144 51.7% 2,130 17.9% 1,021 8.6% 7% VA% is significantly better due to better product mix (increase in sales of Form